dc.date.accessioned | 2022-03-15T16:12:36Z | |
dc.date.available | 2022-03-15T16:12:36Z | |
dc.date.created | 2021-12-02T14:49:45Z | |
dc.date.issued | 2021 | |
dc.identifier.citation | Stillemans, Gabriel Paquot, Adrien Muccioli, Giulio G. Hoste, Emilia Panin, Nadtha Åsberg, Anders Balligand, Jean-Luc Haufroid, Vincent Elens, Laure . Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response. Clinical and Translational Science (CTS). 2021 | |
dc.identifier.uri | http://hdl.handle.net/10852/92488 | |
dc.description.abstract | The purpose of this study was to investigate the potential clinical relevance of estimating the apparent clearance (CL/F) of atorvastatin through population pharmacokinetic (PopPK) modeling with samples collected in a real-life setting in a cohort of ambulatory patients at risk of cardiovascular disease by using an opportunistic sampling strategy easily accessible in clinical routine. A total of 132 pharmacokinetic (PK) samples at a maximum of three visits were collected in the 70 included patients. The effects of demographic, genetic, and clinical covariates were also considered. With the collected data, we developed a two-compartment PopPK model that allowed estimating atorvastatin CL/F relatively precisely and considering the genotype of the patient for SLCO1B1 c.521T>C single-nucleotide polymorphism (SNP). Our results indicate that the estimation of the CL/F of atorvastatin through our PopPK model might help in identifying patients at risk of myalgia. Indeed, we showed that a patient presenting a CL/F lower than 414.67 L h−1 is at risk of suffering from muscle discomfort. We also observed that the CL/F was correlated with the efficacy outcomes, suggesting that a higher CL/F is associated with a better drug efficacy (i.e., a greater decrease in total and LDL-cholesterol levels). In conclusion, our study demonstrates that PopPK modeling can be useful in daily clinics to estimate a patient’ atorvastatin clearance. Notifying the clinician with this information can help in identifying patients at risk of myalgia and gives indication about the potential responsiveness to atorvastatin therapy. | |
dc.language | EN | |
dc.rights | Attribution-NonCommercial-NoDerivatives 4.0 International | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.title | Atorvastatin population pharmacokinetics in a real-life setting: Influence of genetic polymorphisms and association with clinical response | |
dc.type | Journal article | |
dc.creator.author | Stillemans, Gabriel | |
dc.creator.author | Paquot, Adrien | |
dc.creator.author | Muccioli, Giulio G. | |
dc.creator.author | Hoste, Emilia | |
dc.creator.author | Panin, Nadtha | |
dc.creator.author | Åsberg, Anders | |
dc.creator.author | Balligand, Jean-Luc | |
dc.creator.author | Haufroid, Vincent | |
dc.creator.author | Elens, Laure | |
cristin.unitcode | 185,15,23,0 | |
cristin.unitname | Farmasøytisk institutt | |
cristin.ispublished | true | |
cristin.fulltext | original | |
cristin.qualitycode | 1 | |
dc.identifier.cristin | 1963554 | |
dc.identifier.bibliographiccitation | info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Clinical and Translational Science (CTS)&rft.volume=&rft.spage=&rft.date=2021 | |
dc.identifier.jtitle | Clinical and Translational Science (CTS) | |
dc.identifier.doi | https://doi.org/10.1111/cts.13185 | |
dc.identifier.urn | URN:NBN:no-95068 | |
dc.type.document | Tidsskriftartikkel | |
dc.type.peerreviewed | Peer reviewed | |
dc.source.issn | 1752-8054 | |
dc.identifier.fulltext | Fulltext https://www.duo.uio.no/bitstream/handle/10852/92488/1/Stillemans%2BeCTS2021.pdf | |
dc.type.version | PublishedVersion | |